AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET
Company Participants
Liz Shea – Senior Vice President, Investor Relations
Robert A. Michael – C hief Executive Officer
Jeffrey R. Stewart – Executive Vice President, Chief Commercial Officer
Roopal Thakkar – Executive Vice President, Research & Development, Chief Scientific Officer
Scott T. Reents – Executive Vice President, Chief Financial Officer
Carrie Strom – Senior Vice President, AbbVie and President, Global Allergan Aesthetics
Conference Call Participants
Chris Schott – J.P. Morgan
Mohit Bansal – Wells Fargo
Vamil Divan – Guggenheim Securities
Terence Flynn – Morgan Stanley
Chris Shibutani – Goldman Sachs
Trung Huynh – UBS
Geoff Meacham – Citi
James Shin – Deutsche Bank
Carter Gould – Barclays
Steve Scala – Cowen
Luisa Hector – Berenberg
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only until the question-and-answer portion of this call. [Operator Instructions] Today’s call is being recorded.
I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.
Liz Shea
Good morning and thanks for joining us.
Also on the call with me today are Rob Michael, Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; Scott Reents, Executive Vice President, Chief Financial Officer; and Carrie Strom, Senior Vice President, AbbVie and President, Global Allergan Aesthetics.
Before we get started, I’ll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in
Read the full article here
